title: [Gastrojejunostomy for irresectable gastric cancer with pyloric stenosis-new role of surgery in the era of S-1].
abstract: We report a patient with an advanced gastric cancer complicated by pyloric stenosis who was effectively treated by S-1 mono-therapy after gastrojejunostomy. A 62-year-old man consulted a general practitioner for abdominal pain and anorexia. Gastric roentgenography and upper gastrointestinal endoscopy showed gastric cancer(Borrmann Type 3) with pyloric stenosis. He was referred to our department. He underwent laparotomy, which revealed a T4 tumor invading the pancreas head, but neither liver nor peritoneal metastasis. A gastrojejunostomy was made. After the operation, chemotherapy of S-1(120 mg/day, day 1-21)+cisplatin(100 mg/day, day 8)was administered. After 2 courses, level of tumor marker decreased remarkably and abdominal enhanced computed tomography showed a significant size reduction of lymph nodes and that direct invasion to the pancreas was not clear any more. Second laparotomy was carried out and curative surgery was performed. After 4 courses of S-1(120 mg/day, day 1 approximately 28)mono-therapy as adjuvant chemotherapy, bone metastasis was confirmed by scintigram. Then methotrexate+5-FU, irinotecan+cisplatin and cisplatin+paclitaxel were chosen as second-, third-and fourth-line chemotherapy, which were not effective for long. He died 572 a days after the initial surgery. In the past, gastrojejunostomy was regarded as useful palliative treatment for those with gastric outlet stenosis to ameliorate the QOL. As S-1 is taking major role in the chemotherapy for advanced gastric cancer recently, usefulness of bypass surgery for such patients is highlighted even for longer survival time.
authors.affiliation: Department of Surgery 2nd, Hyogo College of Medicine.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Chizuko
authors.initials: C
authors.lastname: Hayashi
authors.forename: Kenji
authors.initials: K
authors.lastname: Koishi
authors.forename: Syoudou
authors.initials: S
authors.lastname: Kojima
authors.forename: Jyunji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Takehira
authors.initials: T
authors.lastname: Yamamura
authors.forename: Hiroto
authors.initials: H
authors.lastname: Miwa
authors.forename: Naohiro
authors.initials: N
authors.lastname: Tomita
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Sasako
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D004338:Drug Combinations; D017809:Fatal Outcome; D015390:Gastric Bypass; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D011707:Pyloric Stenosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000601:surgery*; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D014408:Biomarkers, Tumor; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid